Oura has launched the roadshow for its U.S. initial public offering, targeting a fully-diluted valuation of $15.62 billion to test investor demand for consumer health-tech following a quiet September listing window.
Key Data & Offering Details:
- IPO Proceeds: Oura and existing investors plan to raise up to $2.2 billion by offering 50 million shares priced between $40 and $44.
- Anchor Interest: Pharma titan Eli Lilly indicated interest in buying up to $100 million in shares, alongside investment firm Dragoneer with up to $300 million.
- Revenue Surge: Revenue soared ~74% YoY to $1.21 billion for the 9 months ended June 30, supported by 3.6 million Oura Rings sold in the 12 months through June.
- Subscription Model: Paid memberships are projected to reach ~5.7 million by the end of fiscal 2026 (+96% YoY growth), driving higher-margin recurring software revenues.
- Market Significance: The Finland-founded pioneer (previously valued at $11B) will list on the Nasdaq under ticker “OURA”, with Goldman Sachs, Morgan Stanley, and J.P. Morgan leading the syndicate.
A decisive benchmark for consumer hardware and subscription health-tech valuations in public markets! 📊💍🇺🇸